Compare
Integrated Biopharma Inc vs Nektar Therapeutics vs Ocular Therapeutix, Inc vs Aytu Biopharma, Inc
| Latest fiscal year | Integrated Biopharma Inc INBP | Nektar Therapeutics NKTR | Ocular Therapeutix, Inc OCUL | Aytu Biopharma, Inc AYTU |
|---|---|---|---|---|
| Year ended | 2025-06-30 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $54.35M | $55.23M | $51.95M | $57.57M |
| Revenue growth (YoY) | +8.0% | -43.9% | -18.5% | -13.3% |
| Gross margin | 10.2% | n/a | 87.3% (computed) | 64.0% |
| Operating margin | 3.7% | -253.7% | -519.8% | -14.4% |
| Net margin | 1.5% | -297.1% | -511.9% | -24.8% |
| Net income | $808.0K | -$164.08M | -$265.94M | -$14.25M |
| EPS (Diluted) | $0.03 | -$9.73 | -$1.42 | n/a |
| Operating cash flow | $2.06M | -$208.51M | -$204.88M | $3.28M |
| Free cash flow | $1.87M | -$208.68M | -$216.89M | $3.25M |
| Cash & equivalents | $3.62M | $15.12M | $737.06M | $26.31M |
| Total assets | $24.90M | $280.41M | $808.06M | $105.01M |
| Total liabilities | $4.58M | $190.57M | $153.75M | n/a |
| Shareholders' equity | $20.32M | $89.83M | $654.31M | $35.27M |
| Return on year-end equity | 4.0% | -182.6% | -40.6% | -40.4% |
| Shares outstanding | 31.06M | 20.38M | 215.93M | 10.73M |
Revenue, most recent five fiscal years
| Fiscal year | Integrated Biopharma Inc | Nektar Therapeutics | Ocular Therapeutix, Inc | Aytu Biopharma, Inc |
|---|---|---|---|---|
| Latest | $54.35M Ended 2025-06-30 | $55.23M Ended 2025-12-31 | $51.95M Ended 2025-12-31 | $57.57M Ended 2026-06-30 |
| 1 year earlier | $50.32M Ended 2024-06-30 | $98.43M Ended 2024-12-31 | $63.72M Ended 2024-12-31 | $66.38M Ended 2025-06-30 |
| 2 years earlier | $50.67M Ended 2023-06-30 | $90.12M Ended 2023-12-31 | $58.44M Ended 2023-12-31 | $65.18M Ended 2024-06-30 |
| 3 years earlier | $56.25M Ended 2022-06-30 | $92.06M Ended 2022-12-31 | $51.49M Ended 2022-12-31 | $107.40M Ended 2023-06-30 |
| 4 years earlier | $63.56M Ended 2021-06-30 | $101.91M Ended 2021-12-31 | $43.52M Ended 2021-12-31 | $96.67M Ended 2022-06-30 |